Detalhe da pesquisa
1.
An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes.
Front Immunol
; 15: 1367514, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38515750
2.
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine.
NPJ Vaccines
; 9(1): 40, 2024 Feb 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38383578
3.
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Vaccine
; 41(13): 2184-2197, 2023 03 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36842886
4.
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
Vaccine
; 40(9): 1253-1260, 2022 02 23.
Artigo
Inglês
| MEDLINE | ID: mdl-35115195
5.
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
Vaccine
; 39(45): 6601-6613, 2021 10 29.
Artigo
Inglês
| MEDLINE | ID: mdl-34642088